



2-(Benzhydryl sulfinyl)-N-sec-butylacetamide) isolated from fig augmented trastuzumab-triggered phagocytic killing of cancer cells through interface with Fc γ receptor

Eman T. Ali^a , H. N. K. Al-Salman^b, Khetam H. Rasool^c, Majid S. Jabir^d ,
Tirth R. Ghimire^e, Falah H. Shari^a, Hussein H. Hussein^b, Adil A. Al-Fregi^f,
Ghassan M. Sulaiman^d , Khalil A. A. Khalil^{g,h}, Elsadig M. Ahmed^{g,i} and
Mohamed T. A. Soliman^g

^aDepartment of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah, Basrah, Iraq;

^bDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Basrah, Iraq;

^cDepartment of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq ; ^dDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad, Iraq;

^eDepartment of Zoology, Tri-Chandra Multiple College Tribhuvan University, Kathmandu, Nepal;

^fDepartment of Chemistry, College of Science, University of Basrah, Iraq; ^gDepartment of Medical

Laboratories, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia;

^hDepartment of Medical Laboratory Sciences, Faculty of Medicine and Health Sciences, University of Hodeidah, Yemen;

ⁱDepartment of Clinical Chemistry, Faculty of Medical Laboratory Sciences, University of El Imam El Mahdi, Kosti, Sudan

ABSTRACT

The objective of the current study was to extract 2-(benzhydryl sulfinyl)-N-sec-butylacetamide, a novel compound from fig, and then determine its role in enhancing trastuzumab-triggered phagocytic killing of SKOV-3 cancer cells. In this study, Soxhlet was used to extract the compound from the mature and air-dried fig fruits. The production of the isolated extracts was enhanced by using polar and non-polar solvents. Several solvents, such as methanol, ethyl acetate, chloroform, and n-hexane, were used to isolate the effective compound 2-(benzhydryl sulfinyl)-N-sec-butylacetamide) from the organic layer. UV-spectroscopy, FT-IR, ¹H-NMR, and ¹³C-NMR were applied to identify the purified compound. The *in vitro* and *in vivo* assays demonstrated that the 2-(benzhydryl sulfinyl)-N-sec-butylacetamide) can increase the activity of the phagocytic cells, *via* the interaction with Fc γ receptors, along with trastuzumab, and the pathway can use a model for the therapeutic strategy for effective treatment of ovarian cancer cells.

ARTICLE HISTORY

Received 2 September 2022

Accepted 13 January 2023

KEYWORDS

2-(benzhydryl sulfinyl)-N-sec-butylacetamide); trastuzumab; phagocytosis; cancer cells; Fc γ R

CONTACT Ghassan M. Sulaiman  ghassan.m.sulaiman@uotechnology.edu.iq; Majid S. Jabir  100131@uotechnology.edu.iq

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/14786419.2023.2169861>.

© 2023 Informa UK Limited, trading as Taylor & Francis Group